

## Anti-diabetic Activity of *Crocus sativus* L. (Saffron) Stigma Ethanollic Extract in Alloxan-induced Diabetic Rats

<sup>1</sup>Daryoush Mohajeri, <sup>2</sup>Bahram Amouoghli Tabrizi, <sup>2</sup>Ghafour Mousavi and <sup>3</sup>Mehran Mesgari

<sup>1</sup>Department of Pathobiology, <sup>2</sup>Department of Clinical Sciences,

Faculty of Veterinary Medicine, Islamic Azad University, Tabriz Branch, Tabriz, Iran

<sup>3</sup>Drug Applied Research Center, Tabriz University of Medical Science, Tabriz, Iran

**Abstract:** This research was performed to characterize the hypoglycemic and pancreas-protective effect of ethanollic extract of *Crocus sativus* L. stigma in alloxanized diabetic rats. The ethanollic extract of *Crocus sativus* L. stigma was administered orally and intraperitoneally at different doses (20, 40 and 80 mg kg<sup>-1</sup>) to normal rats. The dose of 40 mg kg<sup>-1</sup> was found to be more effective dose in IP route and it decreases Blood Glucose Level (BGL) by 33.9% in normal healthy rats after 6 h of administration. Although, oral route of *C. sativus* L. also caused significant reductions of blood glucose levels in healthy rats, the effect was minor. The extract administered by IP route at this dose showed an acute hypoglycemic effect in mild and severely alloxan-diabetic rats. Treatment of mild (FBG 120-250 mg dL<sup>-1</sup>) and severely (FBG 250-300 mg dL<sup>-1</sup>) diabetic rats for 14 days with the more effective dose (40 mg kg<sup>-1</sup>) reduces the fasting blood glucose by 41.4% in Mild Diabetic (MD) and 30.7% in Severely Diabetic (SD) rats. After daily treatment with the same dose (40 mg kg<sup>-1</sup>) of ethanollic saffron extract for 14 days to normal as well as MD and SD rats, the plasma insulin levels were assayed. Serum insulin level showed significant increase in diabetic rats (33.3% MD, 27.3% SD). The histopathological studies of pancreas in ethanollic extract treated diabetic groups showed a reversed damage caused by alloxan to the pancreatic islets as almost normal appearance. The findings of our study indicate the hypoglycemic and potential antihyperglycemic nature of the extract, helping in regeneration of damaged pancreas in experimental diabetes.

**Key words:** *Crocus sativus* L. stigmas, antidiabetic activity, herbal medicine

### INTRODUCTION

Diabetes mellitus is a heterogeneous metabolic disorder as old as mankind and its incidence is considered to be high (4-5%) all over the world (Pickup and William, 1997). Diabetes is a chronic disorder of carbohydrate, fat and protein metabolism characterized by elevation of both fasting and post-prandial blood sugar levels. The synthetic oral hypoglycemic agents can produce serious side effects (Akhtar and Iqbal, 1991; Holman and Turner, 1991). In addition, they are not considered safe for use during pregnancy (Lerner, 1985). Furthermore, after the recommendation made by WHO (1980) on diabetes mellitus investigation on hypoglycemic agents from medicinal plants have become more important. Plants have played a major role in the introduction of new therapeutic agents. A medicinal plant, *Galega officinalis*, led to the discovery and synthesis of metformin (Luo *et al.*, 1998) but it is still an extensive demand for

new oral antidiabetic drugs without side effect in human. A multitude of herbs, spices and other plant materials have been described for the treatment of diabetes throughout the world (Ivorra *et al.*, 1989; Marles and Farnsworth, 1995; Kesari *et al.*, 2005; Gupta *et al.*, 2005). The medicinal plants might provide a useful source of new oral hypoglycemic compounds for development of pharmaceutical entities or as a dietary adjunct to existing therapies (Bailey and Day, 1989). Few of the plants used for the treatment of diabetes have received scientific or medical scrutiny and even the WHO expert committee on diabetes recommends that this area warrant further attention (WHO, 1980). Despite the presence of known antidiabetic medicines in the pharmaceutical market, screening for new antidiabetic sources from natural plants is still attractive because they contain substances that have an alternative and safe effect on diabetes mellitus. Saffron (dried stigmas of *Crocus sativus* L.) is the world's most expensive spice and genuine saffron is worth its

weight in gold. This plant belongs to the Iridaceae family and widely cultivated in Iran and other countries such as India and Greece. As a therapeutic plant, saffron is considered an excellent aid for stomach ailments and an antispasmodic, helps digestion and increases appetite. It has been reported that *C. sativus* has hypolipaeamic, anti-inflammatory, antioxidant and anticancer effects. Moreover, according to Commission E, *C. sativus*, is applicable for treatment of nervous disorders, spasms and asthma (Rios *et al.*, 1996; Abe and Saito, 2000; Abdullaev, 2002). Aqueous saffron extract and its active constituent, crocin, are useful agents for the prevention of renal Ischemia-Reperfusion (IR)-induced oxidative injury in rats (Hosseinzade *et al.*, 2005). Furthermore, saffron extract protects against oxidative damage in rat primary hepatocytes. It also suppresses aflatoxin B1-induced hepatotoxic lesions and has a modulatory effect on aflatoxin B1, cytotoxicity. It also has a protective effect on the bladder toxicity, induced by cyclophosphamide (Giaccio, 2004). *Crocus sativus* is a promising compound for reducing cisplatin-toxic side effects including nephrotoxicity; but the exact mechanism by which the saffron extract exert its protective effect against cisplatin-induced toxicity is not yet known (El Daly, 1998). Besides, saffron extract and its active constituent (Crocine) inhibits neuronal cell death induced by both internal and external apoptotic stimuli (Soeda *et al.*, 2001). *Crocus sativus* stigmas given together with cisplatin lead to an even greater decrease in blood glucose than that seen with cisplatin alone (El Daly, 1998). However, adequate characterization of hypoglycemic activity has not yet been done on *Crocus sativus* L. (Saffron) stigma. Therefore, there are no available reports on the pharmacological action of *Crocus sativus* L. (Saffron) stigma until date. This study was designed to elucidate the: 1) hypoglycemic effect of the ethanolic extract of *Crocus sativus* L. (Saffron) stigma in normal and alloxanized diabetic rats; 2) pancreas-protective effect of ethanolic extract of *Crocus sativus* L. (Saffron) stigma on rats with alloxan-induced diabetes.

## MATERIALS AND METHODS

**Plant:** The saffron was used in this study was dedicated by Novin Zaferan Co (Mashhad, Iran) and was identified by the Department of Cultivation and Development of Institute of Medicinal Plants, Tehran, Iran.

**Preparation of the extract:** In the maceration method, 10 g of stigmas were macerated in 500 mL ethanol (80 v/v) for three days. The mixture was subsequently filtered and concentrated under reduced pressure at 40°C. The extract yield was 51% w/w.

**Animals:** Male Wistar rats, 200-250 g obtained from Pasteur Institute of Iran were housed in colony rooms with 12/12 h light/dark cycle at 21±2°C and fed with laboratory pellet chow and given water ad libitum. Animals were acclimatized to their environment for one week prior to experimentation. Investigations using experimental animals were conducted in accordance with the internationally accepted principles for laboratory animal use and care as found in the United States guidelines (United States National Institutes for Health publication no. 85-23, revised in 1985) and our Ethical committee on animal care approved the protocol.

**Induction of diabetes in rats:** After 15 h fasting, rats were injected intraperitoneally with alloxan monohydrate (Sigma chemicals, USA) dissolved in sterile normal saline at a dose of 120 mg kg<sup>-1</sup> body weight.

To confirm diabetes, glycemia was daily determined after the administration of the last alloxan dose. Depending on their Fasting Blood Glucose (FBG) level the animals were divided arbitrarily in to 2 groups (Gupta *et al.*, 2005): Mild Diabetic (MD) animals with FBG of 120-250 mg dL<sup>-1</sup>. Severely Diabetic (SD) animals showing FBG of 250-300 mg dL<sup>-1</sup>.

**Estimations:** Blood glucose was estimated by using one touch glucometer (Accu-chek sensor) of Roche Diagnostics, Germany for regular checkup and the glyucose oxidase method of Biomerieux Laboratory (France), was used for weekly estimations. Blood samples were collected from the retro-orbital plexus. Basal plasma insulin concentrations were determined by radioimmunoassay kit (Pharmacia, Uppsala, Sweden) with a Beta matic counter (Cronex, Dupont, France). The kit included human insulin as standard and <sup>125</sup>I-labelled human insulin antibody, which cross-reacts with rat insulin.

## Biological assays

**Effect in normoglycemic rats using two routes of admonisatration:** Healthy rats fasted for 18 h were used. The animals were separated in 2 groups of 30 rats each. In the first group the treatments were administered orally (PO) and in the other, they were administered through Intraperitoneal (IP) route. The 30 rat in the first group were separated in five subgroups of 6 animals each. Subgroup 1 received isotonic saline solution (ISS, 10 mL kg<sup>-1</sup>) as control; subgroup 2 received tolbutamide (200 mg kg<sup>-1</sup>) as positive control and subgroup 3-5 received orally the variable single doses of 20, 40 and 80 mg kg<sup>-1</sup> of ethanolic saffron extract. In this manner, the other 30 rats in the second group were divided in five subgroups of 6 animals each. Subgroup 6 received Isotonic ISS

(10 mL kg<sup>-1</sup>) as control; subgroup 7 received tolbutamide (200 mg kg<sup>-1</sup>) as positive control and in other subgroups (8-10), ethanolic extract of *Crocus sativus* L. (Saffron) stigma (20, 40 and 80 mg kg<sup>-1</sup>) was IP administered. In all the cases, ethanolic extract and tolbutamide were dissolved in 10 mL kg<sup>-1</sup> body weight of ISS. Blood glucose levels were estimated before and after 2, 4, 6 and 8 h of extract administration.

**Acute effects produced by IP administration of more effective dose of ethanolic saffron extract on the fasted blood glucose levels in mild and severely diabetic rats:**

Mild and severely diabetic rats were randomly assigned to three different groups (n = 6 in each group). Control groups received ISS (10 mL kg<sup>-1</sup>); positive control groups received tolbutamide (200 mg kg<sup>-1</sup>); and extract treated groups received a single dose of ethanolic extract of *Crocus sativus* L. (Saffron) stigma (40 mg kg<sup>-1</sup>). All treatments were administered by IP route. Glycemic levels were determined in fasted animals (t = 0) and at intervals of 120 min for 4 h.

**Effects of the IP daily administration of more effective dose of ethanolic saffron extract on the FBG and plasma insulin levels in MD and SD rats:**

Normal and diabetic rats were randomly assigned to three different groups (n = 8 in each group). The control group received Isotonic Saline Solution (ISS); treated groups received ethanolic extracts of *Crocus sativus* at a dose of 40 mg kg<sup>-1</sup> bw or tolbutamide at a dose of 200 mg kg<sup>-1</sup>. All experiments were performed in overnight fasted rats. All treatments were administered by IP route daily for 2 weeks. In all the cases, ethanolic extract and tolbutamide were dissolved in 10 mL kg<sup>-1</sup> body weight of ISS. Fasting blood glucose and the plasma insulin levels were estimated at the beginning and after 14 days of experiment.

**Histopathological studies:** Histopathological studies of the pancreas were conducted in normal and diabetic rats treated with control vehicle, tolbutamide or ethanolic extract of *C. sativus* L stigma at a dose of 40 mg kg<sup>-1</sup> for 30 days. Animals of the different groups were sacrificed by cervical dislocation and the pancreas was removed. To prepare pancreatic sections for light microscopy, a piece of splenic regions of the pancreas was fixed in 10% buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin-eosin.

**LD<sub>50</sub> experiment:** Wistar rats, of both sex and weighing about 200-250 g were divided into 6 groups of 6 animals each (3 females and 3 males). The test substance was administered in the dose of 5, 20, 40, 60, 80 and 100 mg

kg<sup>-1</sup> IP in a volume of 10 mL kg<sup>-1</sup> to the animals of I, II, III, IV, V and VI groups, respectively. Then the rats were observed continuously for 1 h, intermittently for 6 h and at the end of 24 h for any gross behavioral changes and deaths. Food consumption, feces and urine were also examined at 2 h and then at 6 h intervals for 24 h.

**Statistical analysis:** All biochemical results were expressed as mean±S.D. significant differences among the groups were determined by one-way Analysis of Variance (ANOVA) followed by Bonferroni post-test or unpaired Student's t-test using the SPSS statistical analysis program. Statistical significance was considered at p<0.05.

## RESULTS

**Effect in normoglycemic rats using two routes of administration:**

Results of the effect, of graded doses of ethanolic extract of *C. sativus* stigmas on blood glucose level of normal healthy rats in oral and intraperitoneal routes are presented in Table 1 and 2, respectively. Basal glycemia stays without significant variations in control groups (ISS). The extract in all the three doses (20, 40 and 80 mg kg<sup>-1</sup>) produced significant hypoglycemic effect after 4 h of intraperitoneal administration (p<0.05). However, it was more marked in animals receiving ethanolic extract equivalent to 40 mg kg<sup>-1</sup> body weight. This dose produces a significant fall of 33.9% in BGL after 6 h of IP administration. A fall of 21.5 and 27.3% was observed in BGL at dose 20 and 80 mg kg<sup>-1</sup>, respectively, after 6 h of IP administration. However, slight rise in BGL was observed after 8 h of extract administration. Although, oral route of *C. sativus* shows hypoglycemic effect at 6 h, remarkable effect was observed using intraperitoneal route, with significant glucose reductions. However, when tolbutamide was administered, significant reductions of glycemia at 2 h were observed (p<0.01).

Therefore, subsequent studies were carried out after giving 40 mg kg<sup>-1</sup> of ethanolic extract in MD and SD rats.

**Acute effects produced by I.P. administration on the fasted blood glucose levels in mild and severely diabetic rats:**

Table 3 depicts hypoglycaemic effect of IP administration of ethanolic extract of *C. sativus* stigma in MD and SD rats. Ethanolic extract of *C. sativus* stigma produced a significant reduction of glycemia in the MD rats, from 152.4±5.6 to 133.3±6.6 at 120 min and to 112.4±6.6 mg dL<sup>-1</sup> at 240 min. In SD rats, ethanolic extract of *C. sativus* stigma produced a significant reduction of glycemia from 260.4±9.5 to 210.2±9.2 at 120 min and to 198.8±7.5 mg dL<sup>-1</sup> at 240 min. Tolbutamide produced a

Table 1: Hypoglycemic effect of graded doses of aqueous extract of *Crocus sativus* L. stigma PO administered to healthy rats (mean ± S.D.)

| Experimental group             | Dose (mg kg <sup>-1</sup> ) | Blood glucose levels (mg dL <sup>-1</sup> ) |            |                    |           |           |
|--------------------------------|-----------------------------|---|------------|--------------------|-----------|-----------|
|                                |                             | Pretreatment(h)                             |            | Post treatment (h) |           |           |
|                                |                             | 0   | 2          | 4                  | 6         | 8         |
| ISS (Control)                  | -                           | 85.4±2.4                                    | 87.7±3.2   | 85.9±3.6           | 84.5±2.6  | 83.4±5.2  |
| Tolbutamide (Positive control) | 200                         | 88.6±5.2                                    | 46.3±4.1** | 58.5±5.4*          | 64.9±3.7* | 64.1±3.1* |
| Ethanol extract                | 20                          | 83.4±2.3                                    | 81.7±4.2   | 79.4±5.3           | 72.2±2.2* | 74.3±4.6* |
| Ethanol extract                | 40                          | 86.2±4.1                                    | 83.8±2.2   | 79.7±2.8           | 68.9±3.4* | 70.9±5.3* |
| Ethanol extract                | 80                          | 84.8±4.8                                    | 82.1±4.6   | 78.2±7.3           | 71.1±6.3* | 72.3±4.0* |

Significantly different from the control: \*p<0.05; \*\*p<0.01

Table 2: Hypoglycemic effect of graded doses of aqueous extract of *Crocus sativus* L. stigma IP administered to healthy rats (mean ± S.D.)

| Experimental group             | Dose (mg kg <sup>-1</sup> ) | Blood glucose levels (mg dL <sup>-1</sup> ) |            |                    |           |           |
|--------------------------------|-----------------------------|---|------------|--------------------|-----------|-----------|
|                                |                             | Pretreatment(h)                             |            | Post treatment (h) |           |           |
|                                |                             | 0   | 2          | 4                  | 6         | 8         |
| ISS (Control)                  | -                           | 87.3±4.1                                    | 87.7±3.4   | 87.1±4.7           | 86.1±3.9  | 84.3±4.4  |
| Tolbutamide (Positive control) | 200                         | 86.9±4.2                                    | 44.8±5.1** | 57.3±7.2*          | 63.3±4.6* | 61.7±3.1* |
| Ethanol extract                | 20                          | 81.9±4.7                                    | 80.7±4.4   | 72.7±4.8*          | 64.3±3.9* | 71.1±4.3* |
| Ethanol extract                | 40                          | 88.1±3.4                                    | 79.8±4.6   | 64.6±4.4*          | 58.2±5.1* | 62.7±3.7* |
| Ethanol extract                | 80                          | 86.2±4.2                                    | 80.1±3.9   | 69.7±4.1*          | 62.7±4.6* | 66.6±4.2* |

Significantly different from the control: \*p<0.05; \*\*p<0.01

Table 3: Hypoglycemic effect of the ethanolic extract of *C. sativus* L. stigma IP administered to alloxan induced diabetic rats (mean ± S.D.)

| Experimental groups       | Dose (mg kg <sup>-1</sup> ) | Blood glucose levels (mg dL <sup>-1</sup> ) |            |             |
|---------------------------|-----------------------------|---|------------|-------------|
|                           |                             | t = 0                                       | 120 min    | 240 min     |
| <b>MD rats</b>            |                             |   |            |             |
| Control (vehicle treated) | -                           | 158.4±7.5                                   | 155.4±6.3  | 154.2±7.2   |
| Tolbutamide               | 200                         | 152.3±5.2                                   | 149.2±6.4  | 123.2±7.1*  |
| Ethanol extract           | 40                          | 152.4±5.6                                   | 133.3±6.6* | 112.4±6.6** |
| <b>SD rats</b>            |                             |   |            |             |
| Control (vehicle treated) | -                           | 261.3±8.5                                   | 259.2±7.8  | 258.4±9.3   |
| Tolbutamide               | 200                         | 271.6±8.3                                   | 255.1±8.5  | 219.3±9.6*  |
| Ethanol extract           | 40                          | 260.4±9.4                                   | 210.2±9.2* | 198.8±7.5** |

Significantly different from the respective control: \*p<0.05; \*\*p<0.01

Table 4: Effect of the IP daily administration of ethanolic extract of *Crocus sativus* L. stigma at a dose of 40 mg kg<sup>-1</sup> on blood glucose levels and plasma insulin concentrations in normal and diabetic rats (mean ± S.D.)

| Experimental group        | Blood glucose levels (mg dL <sup>-1</sup> ) |            | Plasma insulin concentrations (µU mL <sup>-1</sup> ) |           |
|---------------------------|---|------------|--|-----------|
|                           | 0 day                                       | 14 day     | 0 day  | 14 day    |
| <b>MD rats</b>            |   |            |  |           |
| Control (vehicle treated) | 156.2±5.8                                   | 152.2±6.4  | 18.9±1.2   | 18.1±1.1  |
| Ethanol extract           | 153.7±7.8                                   | 90±6.7*    | 19.2±1.4   | 25.6±1.6* |
| <b>SD rats</b>            |   |            |  |           |
| Control (vehicle treated) | 263±6.1                                     | 260.5±6.2  | 15.2±0.8   | 14.4±0.6  |
| Ethanol extract           | 260.7±6.5                                   | 180.6±4.5* | 16.1±0.9   | 20.5±1.4* |

Significantly different from the respective control: \*p<0.001

significant attenuation in blood glucose only at 240 min when compared to the diabetic control groups.

**Effect on FBG and Basal plasma insulin concentrations of mild and severely diabetic rats:** Results of the effect, of daily treatment of saffron ethanolic extract with the dose of 40 mg kg<sup>-1</sup> for 2 weeks on blood glucose levels and Basal plasma insulin concentrations of MD and SD alloxanized diabetic rats are presented in Table 4. The stigma extract produced significant hypoglycemic effect

in MD and SD diabetic rats after 2 weeks of administration. This dose produces a significant fall of 41.4% after 2 weeks in MD rats. In this manner, the FBG was decreased by 30.7% in SD rats.

Significant changes in plasma insulin concentrations were observed in both MD and SD rats after daily treatment with the dose of 40 mg kg<sup>-1</sup> for 14 days (MD 33.3%, SD 27.3%). Basal plasma insulin level in normal extract treated group had no significant changes.

**Histopathological studies:** Histological studies of pancreas were carried out in alloxan-induced diabetic rats, which were sacrificed after 1 month of the experiment. Histopathology of the pancreas in diabetic rats showed a spectrum of changes ranging from moderate atrophy with reduced number of islet cells to severe atrophy with an occasional cell, mild to severe destruction of the islets of Langerhans by lymphocytic infiltration. Islet cells showed vacuolation. Exocrine cells were similar to those of the vehicle-injected rat pancreas.

Recovery of pancreatic  $\beta$ -cells after treatment with *Crocus sativus* L stigma in alloxanized mild diabetic rats was prominent as their pancreases were histologically near normal after 1 month of extract administration. Many islet cells were absent showing atrophy of cells. In the pancreas of the extract treated animals vacuolation of the islets cells was also not prominent. Partially reversion also occurred in the damaged pancreatic islets of severe diabetic rats after treatment with *Crocus sativus* L stigma.

**LD<sub>50</sub> experiment (Behavioral effect and toxicity):** The extract of the test substance (*Crocus sativus* L. stigma) was found to be safe for further biological studies as no toxic effect and lethality was observed up to 100 mL kg<sup>-1</sup> IP in rat. Only the consumption of food was increased by 20% in the dose of 80 and 100 mL kg<sup>-1</sup> during 4 h but remaining normal afterwards.

## DISCUSSION

The results showed important differences when the same doses of the ethanolic extract of *Crocus sativus* L. (Saffron) stigma were administered through different routes. Intraperitoneal injection produced the most important reductions of blood glucose levels in healthy rats. Consequently, this route of administration was selected for further investigation.

Ethanolic saffron extract showed a dose-dependent effect on FBG up to a dose of 40 mg kg<sup>-1</sup>. The FBG decreases by 26.6 and 33.9% after 4 and 6 h, respectively in normal rats treated with a single dose of 40 mg kg<sup>-1</sup> of the extract whereas the dose of 80 mg kg<sup>-1</sup> produces a fall of 19.1 and 27.3% in FBG of normal rats after 4 and 6 h of extract administration in IP route. Thus, higher dose of 80 mg kg<sup>-1</sup> did not show any dose-dependent effect although it caused a significant decrease in the FBG level. It is likely that the bigger doses could not produce the expected higher hypoglycaemic effect by the presence of some other substances in the ethanolic extract, which interfere with the hypoglycaemic effect. Such a phenomenon of less hypoglycemic response at higher dose is not uncommon with indigenous plants and has already been observed in *Aegle marmelos* (Sharma *et al.*,

1996a), *Murraya koenigii* (Kesari *et al.*, 2005), *Cinnamomum tamala* (Sharma *et al.*, 1996b) and *Aegle marmelos* (Kesari *et al.*, 2006). However, the dose of 40 mg kg<sup>-1</sup> has almost same effect as of synthetic drug tolbutamide (40 mg kg<sup>-1</sup>) after 6 h of administration.

The present investigation shows that in MD and SD alloxan-diabetic rats, ethanolic extract of *C. sativus* caused significant reductions of blood glucose levels after 2 h of extract administration. Tolbutamide (200 mg kg<sup>-1</sup>) caused a lesser hypoglycemic effect than *C. sativus* ethanolic extract in diabetic rats after 4 h of drug administration. In addition, ethanolic extract of *Crocus sativus* L. (Saffron) stigma caused significant hypoglycemic effect in MD and SD rats after 14 days treatment, while tolbutamide exhibited a mild hypoglycemic activity in these animals.

Tolbutamide is a sulphonylurea that produces experimental and clinical hypoglycemia (in normal animals, in mild alloxan-diabetic animals and in type 2 diabetes) because it induces the release of insulin by the pancreatic beta cells. However, in severe alloxan-diabetic animals, such as in type 1 diabetes, these animals do not have pancreatic beta cells. Thus, tolbutamide does not produce hypoglycemic effect in these situations (Aларcon-Aguilar *et al.*, 2002). Although, the percent fall in blood glucose was found to be more in extract treated MD rats, which have functioning pancreatic  $\beta$ -cells, significant fall in SD rats suggests that the active hypoglycaemic compound present in the ethanolic extract of saffron does not necessarily require the presence of functioning  $\beta$ -cells and acts in the absence of insulin. Therefore, saffron extract may be classified as a direct hypoglycemic agent, by checking hyperglycaemia due to alloxan-induced diabetes, in contrast to the tolbutamide as an indirect agent that act by stimulating the pancreatic beta cells to release more insulin.

The results demonstrated that ethanolic extract of saffron induces significant decrease of plasma glucose levels in diabetic rats and this effect was more potent after repeated IP administration as, a marked normalization of blood glucose levels in these animals was achieved after 2 weeks of treatment. Therefore, the effectiveness of the extract depends, probably on the accumulative effect of active principles. Therefore, it is possible for the test substance to exert its hypoglycaemic activity by both the direct and indirect mechanism. On other hand, a significant change in plasma insulin concentrations was noted in diabetic rats after daily treatment with ethanolic saffron extract for 14 days; but no changes were observed in basal plasma insulin concentrations after treatment in normal rats. Considering the histopathology findings in our study, the mechanism involved in this pharmacological effect, appears to be both pancreatic and extra pancreatic. The results indicate the potential

antihyperglycemic nature of the ethanolic saffron extract, helping in regeneration of damaged pancreas.

The mechanism of alloxan diabetes has been the subject of many investigations and it is now generally accepted that free radicals are selectively involved in the initiation of the damage that ultimately leads to  $\beta$ -cell death (Minami *et al.*, 1999; Vancoa *et al.*, 2004). Therefore, the pancreas is especially susceptible to the action of alloxan-induced free-radical damage. Many substances have been shown to ameliorate the diabetogenicity of alloxan in animals, which protect by reacting with free radicals formed from alloxan during its interaction with the  $\beta$ -cell, or prevent radical formation (Jörns *et al.*, 1999). Recently, it was reported that the saffron extract, crocin and safranal exhibited significant radical scavenging activity and thus antioxidant activity (Assimopoulou *et al.*, 2005) and the present finding indicates that administration of *Crocus sativus* L. stigma confirms the possibility that the major function of the extract is on the protection of vital tissues including the pancreas, thereby reducing the causation of diabetes in these animals.

Therefore, protective effect of saffron extract on pancreas of alloxan-induced diabetic rats could be attributed directly to scavenging activity and for more extent to the regenerative properties of the extract. In conclusion, our study indicates that saffron ethanolic extract produced antihyperglycemic effects in experimental diabetes by providing a regenerative modification against damage caused by alloxan to endocrine cells of the pancreas.

However, ethanolic extract of saffron may exert its hypoglycemic action by mechanisms such as stimulating of glucose uptake by peripheral tissues, inhibition of insulinase activity in both liver and kidney (Achrekar *et al.*, 1991), inhibition of endogenous glucose production or inhibition of renal glucose reabsorption.

### CONCLUSION

Taken in all, the use of this plant in diabetes is then supported but the precise active substance(s), site(s) and cellular and molecular mechanism(s) of this pharmacological effect are still to be determined. In addition, the possible long-term toxic effects of ethanolic saffron extract and its mechanism of protective effects on the pancreas also remain to be clarified.

### ACKNOWLEDGEMENT

The authors are thankful to Islamic Azad University-Tabriz Branch for providing financial assistance.

### REFERENCES

- Achrekar, B., G.S. Kakij, M.S. Pote and S.M. Kelkar, 1991. Hypoglycaemic activity of *Eugenia jambolana* and *Ficus bengalensis*. *In vivo*, 5 (2): 143-147.
- Abdullaev, F.I., 2002. Cancer chemopreventive and tumoricidal properties of saffron (*Crocus sativus* L.). *Exp. Biol. Med.*, 227 (1): 20-25.
- Abe, K. and H. Saito, 2000. Effects of saffron and its constituent crocin on learning behavior and long-term potentiation. *Phytother. Res.*, 14 (3): 149-152.
- Akhtar, M.S. and J. Iqbal, 1991. Evaluation of the hypoglycemic effect of *Achyranthes aspera* in normal and alloxan diabetic rabbits. *J. Ethnopharmacol.*, 31 (1): 49-57.
- Alarcon-Aguilar, F.J., E. Hernandez-Galicia, A.E. Campos-Sepulveda, S. Xolalpa-Molina, J.F. Rivas-Vilchis, L.I. Vazquez-Carrillo and R. Roman-Ramos, 2002. Evaluation of the hypoglycemic effect of *Cucurbita ficifolia* Bouché (*Cucurbitaceae*) in different experimental models. *J. Ethnopharmacol.*, 82 (2-3): 185-189.
- Assimopoulou, A.N., Z. Sinakos and V.P. Papageorgiou, 2005. Radical scavenging activity of *Crocus sativus* L. extract and its bioactive constituents. *Phytother. Res.*, 19 (11): 997-1000.
- Bailey, L.J. and C. Day, 1989. Traditional plant medicine as treatment for diabetes. *Diabetes Care*, 12 (8): 553-564.
- El Daly, E.S., 1998. Protective effect of cysteine and vitamin E, *Crocus sativus* and *Nigella sativa* Extracts on cisplatin-induced toxicity in rats. *J. Pharm. Belg.*, 53 (2): 87-95.
- Giaccio, M., 2004. Crocetin from saffron: An active component of an ancient spice. *Crit. Rev. Food Sci. Nutr.*, 44 (3): 155-172.
- Gupta, R.K., A.N. Kesari, P.S. Murthy, R. Chandra, V. Tandon and G. Watal, 2005. Hypoglycemic and Antidiabetic Effect of Ethanolic Extract of Leaves of *Annona squamosa* L. in Experimental Animals. *J. Ethnopharmacol.*, 99 (1): 75-81.
- Holman, R.R. and R.C. Turner, 1991. Oral Agents and Insulin in the Treatment of NIDDM. In: Pickup J. and G. Williams (Eds.), *Textbook of Diabetes*. Blackwell, Oxford, pp: 407-469.
- Hosseinzadeh, H., H.R. Sadeghnia, T. Ziaee and A. Danaee, 2005. Protective effect of aqueous saffron extract (*Crocus sativus* L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. *J. Pharm. Pharm. Sci.*, 8 (3): 387-93.
- Ivorra, M.D., M. Paya and A. Villar, 1989. A review of natural products and plants as potential antidiabetic drugs. *J. Ethnopharmacol.*, 27 (3): 243-275.

- Jörns, A., M. Tiedge, S. Lenzen and R. Munday, 1999. Effect of superoxide dismutase, catalase, chelating agents and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets *in vitro*. *Free Radic. Biol. Med.*, 26 (9-10): 1300-1304.
- Kesari, A.N., R.K. Gupta, S.K. Singh, S. Diwakar and G. Watal, 2006. Hypoglycemic and antihyperglycemic activity of *Aegle marmelos* seed extract in normal and diabetic rats. *J. Ethnopharmacol.*, 107 (3): 374-379.
- Kesari, A.N., R.K. Gupta and G. Watal, 2005. Hypoglycemic effects of *Murraya koenigii* on normal and alloxan diabetic rabbits. *J. Ethnopharmacol.*, 97 (2): 247-251.
- Larner, J., 1985. Insulin and Oral Hypoglycemic Drugs; Glucagon. In: Gilman, A.G., L.S. Goodman, T.W. Rall and F. Murad (Eds.), *The Pharmacological Bases for Therapeutic*. 7th Edn., Macmillan, New York, pp: 149-151.
- Luo, J., D.M. Fort and T.J. Carlson *et al.*, 1998. *Cryptolepis sanguinolenta*: An ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. *Diabet. Med.*, 15 (5): 367-374.
- Marles, R.J. and N.R. Farnsworth, 1995. Antidiabetic plants and their active constituents. *Phytomedicine*, 2 (2): 137-189.
- Minami, T., M. Shimizu, H. Tanaka, Y. Okazaki and M.G. Cherian, 1999. Metallothionein does not protect mouse endocrine cells from damage induced by alloxan injection. *Toxicology*, 132 (1): 33-41.
- Pickup, J.C. and G. William, 1997. Epidemiology of Diabetes Mellitus. *Textbook of Diabetes*. 2nd Edn. Blackwell, Oxford, 1: 3.1-3.28.
- Rios, J.L., M.C. Recio, R.M. Giner and S. Máñez, 1996. An update review of saffron and its active constituents. *Phytother. Res.*, 10 (3): 189-193.
- Sharma, S.R., S.K. Dwivedi, V.P. Varshney and D. Swarup, 1996a. Antihyperglycemic and Insulin release effects of *Aegle marmelos* leaves in streptozotocin-diabetic rats. *Phytother. Res.*, 10 (5): 426-428.
- Sharma, S.R., S.K. Dwivedi and D. Swarup, 1996b. Hypoglycaemic and hypolipidemic effects of *Cinnamomum tamala* Nees leaves. *Indian J. Exp. Biol.*, 34 (4): 372-374.
- Soeda, S., T. Ochiai, L. Paopong, H. Tanaka, Y. Shoyama and H. Shimeno, 2001. Crocin suppresses tumor necrosis factor alpha-induced cell death of neuronally differentiated PC-12 cells. *Life Sci.*, 69 (24): 2887-98.
- Vanco, J., O. Svajlenová, E. Ramanska, J. Muselik and J. Valentová, 2004. Antiradical activity of different copper (II) Schiff base complexes and their effect on alloxan-induced diabetes. *J. Trace. Elem. Med. Biol.*, 18 (2): 155-161.
- WHO, 1980. Expert committee on Diabetes mellitus, Technical reports series World Health Organisation, Geneva.